Pfizer, Astellas report detailed data for Xtandi in non-metastatic CRPC

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) reported detailed data from the Phase III PROSPER trial to treat non-metastatic castration-resistant prostate cancer (CRPC) showing that once-daily 160 mg oral Xtandi enzalutamide plus androgen deprivation therapy led to

Read the full 388 word article

User Sign In